

## PRODUCT INFORMATION

<b>Clone ID</b>	<b>Warning:</b> Undefined variable \$hasAttributeValueDescription in C:\wwwroot\mirror.dimabio.com\wp-content\plugins\woocommerce-print-products\publicclass-woocommerce-print-products-public.php on line 2806 1A1
<b>Target</b>	Dxd
<b>Synonyms</b>	N.A.
<b>Host Species</b>	Rabbit
<b>Description</b>	Anti-Dxd antibody(1A1); Rabbit mAb
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	N.A.
<b>IgG type</b>	Rabbit IgG
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	N.A.
<b>Applications</b>	ELISA
<b>Recommended Dilutions</b>	ELISA 1:5000-10000
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Yefei Storage</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	Dxd is a potent anti-cancer drug, acting as an alkaloid camptothecin analog and a DNA topoisomerase I inhibitor. It forms a stable complex with topoisomerase I and DNA, impeding DNA replication and inducing cancer cell death. Dxd is utilized as a payload in specific antibody-drug conjugates (ADCs), with examples such as trastuzumab deruxtecan targeting HER2 and patritumab deruxtecan targeting HER3.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

### ELISA assay to evaluate Anti-Dxd Antibody 0.2µg Human IgG-Dxd per well




Figure1. Elisa plates were pre-coated with IgG-Dxd (0.2µg/per well). Serial diluted anti-Dxd monoclonal antibody (DME101024) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-Dxd monoclonal antibody binding with IgG-Dxd is 4.440ng/ml.

